Independent determinants of blast phase survival duration
| Model and factors . | P . | Hazard ratio . |
|---|---|---|
| Model 1 | ||
| Age 60 y or older | .008 | 2.7 |
| Peripheral blasts 20% or more | .009 | 2.4 |
| Prior splenectomy | .02 | 2.5 |
| Model 2 | ||
| Age 60 y or older | .03 | 2.3 |
| Peripheral blasts 20% or more | .01 | 2.4 |
| Prior splenectomy | .03 | 2.4 |
| Treated for blast phase | .005 | 0.34 |
| Model and factors . | P . | Hazard ratio . |
|---|---|---|
| Model 1 | ||
| Age 60 y or older | .008 | 2.7 |
| Peripheral blasts 20% or more | .009 | 2.4 |
| Prior splenectomy | .02 | 2.5 |
| Model 2 | ||
| Age 60 y or older | .03 | 2.3 |
| Peripheral blasts 20% or more | .01 | 2.4 |
| Prior splenectomy | .03 | 2.4 |
| Treated for blast phase | .005 | 0.34 |
The first multivariate model considers baseline characteristics only. When whether patients received antileukemia therapy was added to the model, treatment emerged as the strongest independent predictor of survival.